The IDH mutant form is a major part of the secondary GBM group (diffuse astrocytoma, WHO CNS grade 4 as per the 2021 guidelines)-originating on the basis of a previous low-grade glioma. The gene discussed is IDH2; the disease is central nervous system cancer.